new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors




Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22016002268501/28/16 Heterocyclylamines as pi3k inhibitors
32016002410901/28/16 Tricyclic fused thiophene derivatives as jak inhibitors
42016002411701/28/16 Heterocyclylamines as pi3k inhibitors
52016001569501/21/16 Tricyclic fused thiophene derivatives as jak inhibitors
62016000971101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
72016000971201/14/16 Imidazopyridines and imidazopyrazines as lsd1 inhibitors
82016000971401/14/16 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
92016000972001/14/16 Imidazopyrazines as lsd1 inhibitors
102016000972101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
112016000972601/14/16 Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
122016000079501/07/16 Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
132015036109412/17/15 Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
142015034295212/03/15 Treatment of chronic neutrophilic leukemia (cnl) and atypical chronic myeloid leukemia (acml) by inhibitors of jak1
152015034449712/03/15 Processes of preparing a jak1 inhibitor and new forms thereto
162015032953411/19/15 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
172015032956111/19/15 Amido compounds and their use as pharmaceuticals
182015031518511/05/15 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
192015030749310/29/15 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
202015029170110/15/15 Methods for treating disorders associated with human signal peptide-containing molecules
212015028439010/08/15 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
222015025079009/10/15 Topical formulation for a jak inhibitor
232015024604609/03/15 Jak1 inhibitors for the treatment of myelodysplastic syndromes
242015023849208/27/15 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
252015022537508/13/15 Cyclopropylamines as lsd1 inhibitors
262015022537908/13/15 Cyclopropylamines as lsd1 inhibitors
272015022539408/13/15 Cyclopropylamines as lsd1 inhibitors
282015022540108/13/15 Cyclopropylamines as lsd1 inhibitors
292015022541108/13/15 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
302015021817408/06/15 Processes for preparing jak inhibitors and related intermediate compounds
312015021069207/30/15 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
322015019037807/09/15 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
332015018380507/02/15 Processes and intermediates for making a jak inhibitor
342015017560406/25/15 Tricyclic heterocycles as bet protein inhibitors
352015016490006/18/15 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
362015014834205/28/15 Bicyclic heterocycles as bet protein inhibitors
372015014834805/28/15 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
382015014837205/28/15 Bicyclic heterocycles as bet protein inhibitors
392015014837505/28/15 Bicyclic heterocycles as bet protein inhibitors
402015013367405/14/15 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
412015008763203/26/15 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
422015008766203/26/15 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
432015006544703/05/15 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
442015006548403/05/15 Sustained release dosage forms for a jak1 inhibitor
452015005726502/26/15 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
462015002505601/22/15 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
472015001717301/15/15 Antibodies to human transmembrane proteins
482015001154001/08/15 Tricyclic heterocycles as bet protein inhibitors
492015000416501/01/15 Secreted proteins
502014037729212/25/14 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
512014037840012/25/14 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
522014037121612/18/14 Purinone derivatives as hm74a agonists
532014034303011/20/14 Bipyrazole derivatives as jak inhibitors
542014031596210/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
552014027503009/18/14 Tricyclic heterocycles as bet protein inhibitors
562014027503109/18/14 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
572014027512709/18/14 Substituted heteroaryl fused derivatives as pi3k inhibitors
582014025694109/11/14 Processes and intermediates for making a jak inhibitor
592014024913209/04/14 Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
602014024208608/28/14 Polynucleotides encoding signal peptide-containing molecules
612014024330808/28/14 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
622014024336008/28/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
632014022727508/14/14 Methods of treating and diagnosing pancreatitis
642014022727808/14/14 Antibodies to human signal peptide-containing proteins
652014022834608/14/14 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
662014022137908/07/14 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
672014020021607/17/14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
682014020022707/17/14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
692014018753007/03/14 Aza spiro alkane derivatives as inhibitors of metalloproteases
702014017140506/19/14 Fused pyrazoles as fgfr inhibitors
712014017140906/19/14 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
722014015528806/05/14 Methods for diagnosing cancer
732014015537706/05/14 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
742014015540406/05/14 Piperazinylpiperidine derivatives as chemokine receptor antagonists
752014013535005/15/14 Sustained-release dosage forms of ruxolitinib
762014012119805/01/14 Tricyclic fused thiophene derivatives as jak inhibitors
772014012122205/01/14 Pyrimidinones as pi3k inhibitors
782014006644803/06/14 Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
792014005690602/27/14 Secreted proteins
802014005791202/27/14 Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
812014004581402/13/14 Pyrazine derivatives as fgfr inhibitors
822014003134401/30/14 Azepine inhibitors of janus kinases
832014002366301/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
842014001837401/16/14 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
852014000516601/02/14 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
862014000521001/02/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
872013034515712/26/13 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
882013034522412/26/13 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
892013032451512/05/13 Imidazotriazines and imidazopyrimidines as kinase inhibitors
902013025319009/26/13 Processes for preparing jak inhibitors and related intermediate compounds
912013025319109/26/13 Processes for preparing jak inhibitors and related intermediate compounds
922013025319309/26/13 Processes for preparing jak inhibitors and related intermediate compounds
932013024378109/19/13 Signal peptide-containing proteins
942013024492709/19/13 Polynucleotides encoding signal peptide-containing molecules
952013024499909/19/13 Substituted heterocyclic compounds
962013022476908/29/13 Methods of using chemokine panec-1 antibodies
972013022555608/29/13 Azetidine and cyclobutane derivatives as jak inhibitors
982013019025007/25/13 Polynucleotides encoding human signal peptide-containing proteins
992013017759007/11/13 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1002013013768105/30/13 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1012013012324605/16/13 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1022013011623005/09/13 3-aminopyrrolidine derivatives as modulators of chemokine receptors
1032013009614404/18/13 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
1042013005894203/07/13 Human beta-adrenergic receptor kinase polypeptide and methods
1052013005983503/07/13 Heterocyclylamines as pi3k inhibitors
1062013006002603/07/13 Processes and intermediates for making a jak inhibitor
1072013004596302/21/13 Cyclohexyl azetidine derivatives as jak inhibitors
1082013001803401/17/13 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
1092013001806801/17/13 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
1102012032978212/27/12 Azepine inhibitors of janus kinases
1112012030146411/29/12 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
1122012029591211/22/12 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1132012027080910/25/12 Human transmembrane proteins
1142012012285805/17/12 Lactam compounds and their use as pharmaceuticals
1152012004096402/16/12 N-substituted piperidines and their use as pharmaceuticals
1162012003517202/09/12 Purinone derivatives as hm74a agonists
1172012001493701/19/12 Human beta-adrenergic receptor kinase polypeptide and methods
1182012001592801/19/12 Amido compounds and their use as pharmaceuticals
1192011025121510/13/11 Macrocyclic compounds and their use as kinase inhibitors
1202011021296709/01/11 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
1212011020775408/25/11 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
1222011013678106/09/11 Imidazotriazines and imidazopyrimidines as kinase inhibitors
1232011008681004/14/11 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1242011008215904/07/11 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1252011005321703/03/11 Polynucleotides encoding signal peptide-containing molecules
1262010027933311/04/10 Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
1272010025611410/07/10 Amido compounds and their use as pharmaceuticals
1282010024067109/23/10 Substituted heterocyclic compounds
1292010020303908/12/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1302010019080407/29/10 Macrocyclic compounds and their use as kinase inhibitors
1312010017390107/08/10 Substituted heterocyclic compounds
1322010013740106/03/10 2-methylprop anamides and their use as pharmaceuticals
1332010011950305/13/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1342010009961704/22/10 Secreted proteins
1352009031840512/24/09 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1362009029194611/26/09 Lactam compounds and their use as pharmaceuticals
1372009028677411/19/09 Purinone derivatives as hm74a agonists
1382009028677811/19/09 Macrocyclic compounds and their use as kinase inhibitors
1392009027468011/05/09 Human phospholipases
1402009023390309/17/09 Azetidine and cyclobutane derivatives as jak inhibitors
1412009021576608/27/09 Tetracyclic inhibitors of janus kinases
1422009019788708/06/09 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1432009018195907/16/09 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1442009012464905/14/09 Aza spiro alkane derivatives as inhibitors of metalloproteases
1452009008844604/02/09 Purinone derivatives as hm74a agonists
1462009007626903/19/09 Purinone derivatives as hm74a agonists
1472012026367610/18/12 Compositions, methods and kits relating to her-2 cleavage
1482012005807903/08/12 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1492012001498901/19/12 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1502011031147912/22/11 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1512011022321009/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1522011022415709/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1532011017227907/14/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1542011016518807/07/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1552011008683504/14/11 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1562009029880812/03/09 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1572009019786908/06/09 Azepine inhibitors of janus kinases



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###